share_log

Piper Sandler Reiterates Overweight on Immunic, Maintains $28 Price Target

Benzinga ·  Jul 16 23:44

Piper Sandler analyst Yasmeen Rahimi reiterates Immunic (NASDAQ:IMUX) with a Overweight and maintains $28 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment